Press coverage about ProQR Therapeutics (NASDAQ:PRQR) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ProQR Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.5975226450834 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- ProQR trumpets big results from treatment trials (baystreet.ca)
- Small-Cap Snapshot: ProQR Therapeutics shares climb on early-stage clinical trial to treat rare childhood blindness disorder (proactiveinvestors.co.uk)
- ProQR's stock rockets to pace all gainers after upbeat drug trial results (finance.yahoo.com)
- Biotech Stocks & Marijuana Stocks Moving Higher on Wednesday (finance.yahoo.com)
- Here's Why ProQR Therapeutics N.V. Is Skyrocketing Today (finance.yahoo.com)
Several research firms have weighed in on PRQR. ValuEngine downgraded shares of ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 30th. Zacks Investment Research upgraded shares of ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Thursday, August 9th. HC Wainwright reiterated a “buy” rating on shares of ProQR Therapeutics in a research report on Monday, July 2nd. Finally, Chardan Capital reiterated a “buy” rating and issued a $9.00 price target on shares of ProQR Therapeutics in a research report on Monday, August 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $13.80.
PRQR traded down $1.35 during trading on Thursday, hitting $16.20. The company’s stock had a trading volume of 45,674 shares, compared to its average volume of 92,054. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.26. ProQR Therapeutics has a one year low of $2.75 and a one year high of $17.55. The company has a market capitalization of $243.73 million, a PE ratio of -8.35 and a beta of 0.63.
ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.15. equities analysts forecast that ProQR Therapeutics will post -1.35 earnings per share for the current fiscal year.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Recommended Story: Penny Stocks
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.